Recurrent or Metastatic
3 clinical trials · Condition
◉ Watch Recurrent or Metastatic
| Record | Firm | Date |
|---|---|---|
| Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer (NCT06413992) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-10 |
| KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT05294172) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-06-07 |
| KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT03848286) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2019-03-06 |
Track Recurrent or Metastatic automatically
Every clearance here is in the API, with alerts when new ones post.